Abingdon Health PLC announced on Wednesday that it will provide Boots UK Ltd with rapid lateral flow self-tests to be sold under the Boots own brand label.
The York, England-based lateral flow technology company has developed Iron and Vitamin D deficiency tests which will be made available from spring onwards online and in stores across the UK in partnership with Crest Medical Ltd, a Warrington-based medical supplies company.
Abingdon Chief Executive Officer Chris Yates said: ‘We take immense pride in the quality of our service and ensure a seamless supply of innovative lateral flow self-tests to ensure our partners requirements are met.’
This as a significant step in strengthening the company’s position in a growing market. In 2023 consumer adoption of self-tests was worth $7.90 billion and the lateral flow market is expected to reach $23 billion by 2027.
Abingdon shares were up 12% to 9.52 pence in London on Wednesday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
